AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life ...

HATFIELD, PA.--(BUSINESS WIRE)--Data-driven food allergy diagnostics company, AllerGenis, LLC today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX) ...

Luminex’s xMAP Technology will be deployed by the HPA project to perform flexible and high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples. The same technology ...

Luminex has won an award of $683,500 from the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development of its Covid-19 multiplex antibody test. The award is for a ...

Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP® Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to ...

Histone post-translational modifications (PTMs) play pivotal roles in chromatin dynamics and function, with alterations in the healthy profile associated with diverse human pathologies. The regulation ...

The Tecan Group (SIX Swiss Exchange: TECN) and Luminex Corporation (Nasdaq: LMNX) have announced that they will collaborate on the development of a new automated newborn screening solution that will ...

Luminex Corporation has announced plans for the annual Planet xMAP USA end-user technology symposium. Planet xMAP USA 2006 will be held in Dallas, Texas, May 15-17, at The Adolphus Hotel. The Planet ...

Luminex Corporation ( LMNX) recently announced that its xMAP Technology will play a significant role in the biobank profiling research within the Human Protein Atlas (HPA) project. Shares of Luminex ...